依维莫司是一种哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂,可改善晚期激素受体阳性/人表皮生长因子受体2阴性(hormone receptor-positive/hu-man epidermal growth factor receptor 2-negative,HR+/HER2-)乳腺癌患者的预后.然而,依维莫司耐药日益发展,缺乏有效的标志物预测其疗效,对其临床应用造成了挑战.针对这一重要的临床问题,全文整理了近年来mTOR抑制剂的耐药机制及依维莫司疗效预测标志物的相关研究,以期提供参考.
Abstract
Everolimus,a mammalian target of rapamycin(mTOR)inhibitor,has been shown to improve survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)advanced breast cancer.However,resistance to everolimus has been in-creasingly developed,and there is no efficient biomarker to predict its efficacy,which becomes a challenge for the clinical use of everolimus.This paper reviews the mechanisms of resistance to mTOR inhibitor and potential markers that can predict the efficacy of everolimus.
关键词
乳腺癌/耐药/哺乳动物雷帕霉素靶蛋白抑制剂/依维莫司/疗效标志物
Key words
breast cancer/drug resistance/mammalian target of rapamycin inhibitor/everolimus/predictive marker
维普
万方数据